{
    "organizations": [],
    "uuid": "659f2210588ec8473925e29f27d966183851a961",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-trovagene-completes-cycle-one-dosi/brief-trovagene-completes-cycle-one-dosing-in-first-patient-enrolled-in-phase-1b-2-clinical-trial-of-pcm-075-idUSASB0C47E",
    "ord_in_thread": 0,
    "title": "BRIEF-Trovagene Completes Cycle-One Dosing In First Patient Enrolled In Phase 1B/2 Clinical Trial Of PCM-075",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 6 (Reuters) - Trovagene Inc:\n* TROVAGENE ANNOUNCES COMPLETION OF CYCLE-ONE DOSING IN FIRST PATIENT ENROLLED IN ITS PHASE 1B/2 CLINICAL TRIAL OF PCM-075 IN ACUTE MYELOID LEUKEMIA (AML) Source text for Eikon: Further company coverage:\n ",
    "published": "2018-02-06T21:21:00.000+02:00",
    "crawled": "2018-02-07T22:04:19.002+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "trovagene",
        "inc",
        "trovagene",
        "announces",
        "completion",
        "dosing",
        "first",
        "patient",
        "enrolled",
        "phase",
        "clinical",
        "trial",
        "acute",
        "myeloid",
        "leukemia",
        "aml",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}